ClinicalTrials.gg
CompletedNCT04735822Updated May 11, 2022

A Phase I Study to Evaluate the Taste of Belumosudil Oral Suspensions & Assess Relative Bioavailability

An Early Phase 1 interventional study of Part 1: Belumosudil 40 mg/mL Sequence ABFCED and Part 1: Belumosudil 40 mg/mL Sequence BCADFE in Healthy Volunteers, sponsored by Kadmon Corporation, LLC. Completed at 1 site in United Kingdom. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-05-11.

Sponsored by Kadmon Corporation, LLC (part of Sanofi) · Early Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Sep 2021, 5 years 2 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
Male
01

Study summary

This is a single-center, randomized, open-label, 2-part study in healthy male subjects to evaluate the taste profile of different belumosudil oral suspensions and the relative bioavailability of those chosen oral suspensions of belumosudil compared to oral tablets of belumosudil.

Part 1 is an open-label, randomized single-period study of oral suspensions of belumosudil 40 mg/mL delivered in 6 different vehicles. Approximately 12 healthy male subjects, 2 subjects in each of 6 groups, will be administered a single dose of belumosudil 40 mg/mL in 6 different vehicles (Vehicles 1, 2, 3, 4, 5, and 6) in corresponding Regimens A, B, C, D, E, and F in different sequences of the 6 vehicles. All subjects will receive 1 dose of all belumosudil in all 6 vehicles which are as follows: ABFCED; BCADFE; CDBEAF; DECFBA; EFDACB; and FAEBDC.

Part 2 is a single-center, open-label, randomized, 3-period design to assess the relative bioavailability of a selected belumosudil suspension formulation compared to the oral belumosudil. Tablet reference and the effect of food on the selected belumosudil suspension formulation in 18 healthy male subjects. Subjects will be randomized prior to the administration of the first dose of IMP to 1 of 6 treatment sequences (GHI, HIG, IGH, IHG, GIH and HGI), with 3 subjects assigned to each treatment sequence where:

Regimen G--oral belumosudil 200 mg tablet (reference) with the subject fed; Regimen H--belumosudil powder 200 mg for oral suspension or belumosudil 200 mg oral suspension with the subject fasting; and Regimen I--belumosudil 200 mg powder for oral suspension or belumosudil 200 mg oral suspension with the subject fed.

Read the detailed description

PART 1

This is a single center, open-label, randomized, single period design to assess the taste profile of different novel regimens from bottles containing 1200 mg of belumosudil. Twelve healthy subjects will receive single doses of the 6 bottled oral formulations:

Regimen A: belumosudil 40 mg/mL delivered by Vehicle 1 (sterile water for irrigation); Regimen B: belumosudil 40 mg/mL delivered by Vehicle 2 (low sucralose solution); Regimen C: belumosudil 40 mg/mL delivered by Vehicle 3 (high sucralose solution); Regimen D: belumosudil 40 mg/mL delivered by Vehicle 4 (orange flavor with low sucralose solution); Regimen E: belumosudil 40 mg/mL delivered by Vehicle 5 (tropical fruit blend with low sucralose solution); Regimen F: belumosudil 40 mg/mL delivered by Vehicle 6 (lemon flavor with low sucralose solution)

Subjects will sip the belumosudil oral suspension and then spit it out. The maximum dose is belumosudil 200 mg.

On Day 1, two subjects each will be randomized to 1 of 6 treatment sequences with belumosudil:

ABFCED (2 subjects); BCADFE (2 subjects); CDBEAF (2 subjects); DECFBA (2 subjects); EFDACB (2 subjects); FAEBDC (2 subjects)

Subjects will undergo preliminary screening procedures to determine their eligibility for Part 1 of the study at a screening visit (Day -28 to Day -2 of Part 1). Subjects will be admitted to the clinical unit on the morning prior to investigational medicinal product (IMP) administration (Day -1) for confirmation of eligibility and baseline procedures. Prior to the first administration of IMP (either Day -1 or prior to the completion of breakfast [pre-dose] on Day 1), subjects will be given a training questionnaire using an example fluid (e.g., orange juice/squash).

In the evening of Day -1, subjects will receive a light snack and will then fast from all food and drink (except water). Following the overnight fast (approximately 8 hours), subjects will consume a standard breakfast. Following breakfast, subjects will brush their teeth using tap water (toothpaste will not be permitted). The first dose of IMP will be administered approximately 2 hours after breakfast has been completed.

Subjects will receive the test belumosudil from bottles in regimens according to a randomization schedule. Each regimen will follow the same study design. Subjects will receive a single dose of belumosudil 40 mg/mL as an oral suspension, which will be held in the mouth for approximately 1 minute before it is expectorated, and will subsequently complete a written taste/palatability questionnaire individually and privately. No belumosudil is to be consumed.

There will be a washout period of 30 min ± 10 min (minimum 20 min) between tasting each regimen (inclusive of palate cleansing). During this time, subjects will cleanse their palates using tap water (administered freely in 50 mL aliquots) and unsalted crackers before further tasting. It is expected that all regimens will be tasted on the same day.

A single plasma pharmacokinetic (PK) sample will be taken approximately 1 hour post-final dose (prior to discharge from the clinical unit). This sample will be retained and only analyzed in case of accidental swallowing of the formulation by a subject and/or for the purpose of investigating a possible treatment-emergent adverse event (TEAE) related to the IMP.

Subjects will remain on site until 1 hour post-final taste/palatability assessment. To ensure the ongoing well-being of the subjects, a follow-up phone call will take place 3 to 7 days after the final dose. If a subject reports any adverse events (AEs) after discharge which is a cause for concern, they will be required to attend the clinical unit for a follow-up assessment. This follow-up visit will be considered an unscheduled visit.

Following the completion of Part 1, an interim data review will be performed during which the taste/palatability assessment data will be reviewed to determine the flavor system that will be incorporated into the IMP formulation for administration in Part 2.

PART 2

This is a single-center, open-label, randomized, 3-period design to assess the relative bioavailability of a selected belumosudil suspension formulation from Part 1 compared to the belumosudil oral tablet. Eighteen subjects will receive single doses of the following:

Regimen G = 200 mg belumosudil tablet (reference drug) orally when subjects are fed; Regimen H = 200 mg belumosudil powder for oral suspension or belumosudil oral suspension when subjects are fasting; and Regimen I = 200 mg belumosudil powder for oral suspension or belumosudil oral suspension when subjects are fed.

On Day 1, three subjects each will be randomized to 1 of 6 treatment sequences with belumosudil:

GHI (3 subjects); HIG (3 subjects); IGH (3 subjects); IHG (3 subjects); GIH (3 subjects); HGI (3 subjects)

Subjects will undergo preliminary screening procedures to determine their eligibility for Part 2 of the study at a screening visit (Day -28 to Day -2 of Part 2). Subjects who have taken part in Part 1 of the study are permitted to take part in Part 2.

Each study period will follow a similar design. Subjects will be admitted to the clinical unit on the morning prior to the first IMP administration (Day -1 of Period 1) for confirmation of eligibility and baseline procedures. For Regimen H only, subjects will be given a training questionnaire using an example fluid (e.g., orange juice/squash) prior to IMP administration. This will be performed either on Day -1 (only applicable if Regimen H is administered in Period 2 or 3) or prior to the completion of breakfast (pre-dose) on Day 1.

Subjects will receive a single dose of IMP in the morning of Day 1 following an overnight fast of a minimum of 10 hours (Regimen H, fasted state) or following a standard breakfast (Regimens G and I, fed state). Blood samples will be collected at regular intervals for PK analysis. Following administration of Regimen H, subjects will complete a written taste/palatability questionnaire individually and privately.

Subjects will reside in the clinical unit for 10 consecutive nights that will cover all 3 treatment periods. All subjects will remain on site until 72 h post-final dose for safety and PK assessments. There will be a minimum washout period of 3 days between each IMP administration. To ensure the ongoing well-being of the subjects, a follow-up phone call will take place 3 to 7 days after the final dose. If a subject reports any AEs after discharge which is a cause for concern, they will be required to attend the clinical unit for a follow-up assessment. This follow-up visit will be considered an unscheduled visit.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • Belumosudil
  • KD025
  • SLx-2119
  • ROCK inhibitor
  • Healthy male subjects
03

In context

Lead sponsor

Kadmon Corporation, LLC is the lead sponsor of 20 studies on the registry; none are open to participants now.

First submitted before Kadmon Corporation, LLC became part of Sanofi.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy males
  2. Aged 18 to 55 years inclusive at the time of signing .
  3. of 18.0 to 32.0 kg/m\^2 at screening
  4. Body weight ≥ 50 kg at screening
  5. Must be willing and able to communicate and participate in the entire study
  6. Must provide written informed consent
  7. Must agree to adhere to the requirements

Exclusion criteria

Exclusion Criteria:

  1. Subjects who have received any IMP in a previous clinical research study within the 90 days prior to Day 1 (Part 2 only)
  2. Subjects who are or are immediate family members of a study site or sponsor employee
  3. Subjects who have previously been administered IMP in Part 2 of this study. Subjects who have taken part in Part 1 are permitted to take part in Part 2
  4. Evidence of current SARS-CoV-2 infection
  5. history or presence of acute or chronic bacterial, fungal, or viral infection (e.g., pneumonia, septicemia) within the 3 months or 90 days prior to screening
  6. Any subject with clinically significant symptoms of COVID-19 in the last 4 weeks, including but not limited to fever, new and persistent cough, breathlessness or loss of taste or smell, as per the judgement of the investigator
  7. Known or suspected , disorder, or any history of known or suspected congenital or acquired immunodeficiency state or condition that would compromise the participant's immune status or any factor that would predispose participants to develop infection (e.g., open skin lesions, recurrent issues related to poor dentition, perianal fissures, history of splenectomy, primary immunodeficiency)
  8. History of any drug or alcohol abuse in the past 2 years
  9. Regular alcohol consumption in males > 21 units per week (1 unit = ½ pint beer, or a 25 mL shot of 40% spirits, 1.5 to 2 units = 125 mL glass of wine, depending on type)
  10. A confirmed positive alcohol breath test at screening or admission
  11. Current smokers and those who have smoked within the last 12 months. A confirmed breath carbon monoxide reading of greater than 10 ppm at screening or admission.
  12. Current users of e-cigarettes and nicotine replacement products and those who have used these products within the last 12 months
  13. Subjects with pregnant or lactating partners
  14. Subjects who do not have suitable veins for multiple venipunctures/cannulation as assessed by the investigator or delegate at screening
  15. Clinically significant abnormal clinical chemistry, hematology or urinalysis as judged by the investigator. Subjects with Gilbert's Syndrome are allowed.
  16. Confirmed positive drugs of abuse test result.
  17. Positive surface antigen, virus antibody, or antibody results
  18. Evidence of renal impairment at screening, as indicated by an estimated (CLcr) of \< 80 mL/min using the Cockcroft-Gault equation (Part 2 only)
  19. History of clinically significant cardiovascular, renal, hepatic, dermatological, chronic respiratory, gastrointestinal (GI) disease, or neurological or psychiatric disorder as judged by the investigator
  20. Subject has a history or presence of any of the following (Part 2 only):

    • Cytopenias
    • Active GI disease requiring therapy
    • Hepatic disease and/or or aspartate aminotransferase > (ULN)
    • Renal disease and/or serum creatinine > ULN
    • Other condition known to interfere with the absorption, distribution, metabolism or excretion of drugs
  21. Subjects with a history of cholecystectomy or gall stones (Part 2 only)
  22. Subject has intervals >450 msec at screening or admission (Part 2 only)
  23. Serious adverse reaction or serious to any drug or the formulation
  24. Presence or history of clinically significant allergy requiring treatment, as judged by the investigator. Hay fever is allowed unless it is active
  25. Donation of blood or plasma within the previous 3 months or loss > 400 mL of blood
  26. Subjects who are taking or have taken any prescribed or over-the-counter drug or herbal remedies (other than up to 4 g of paracetamol per day) in the 14 days prior to IMP administration, including proton pump inhibitors. Exceptions may apply on a case by case basis, if considered not to interfere with the objectives of the study, as determined by the investigator.
  27. Failure to satisfy the investigator of fitness to participate for any other reason
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Part 1: Belumosudil Sequence ABFCED

    Subjects receive 1 dose of belumosudil 40 mg/mL in oral suspension in the following sequence: Regimen A (delivered by Vehicle 1); Regimen B (delivered by Vehicle 2); Regimen F (delivered by Vehicle 6); Regimen C (delivered by Vehicle 3); Regimen E (delivered by Vehicle 5); Regimen D (delivered by Vehicle 4);

    Drug: Part 1: Belumosudil 40 mg/mL Sequence ABFCED

  • Experimental
    Part 1: Belumosudil Sequence BCADFE

    Subjects receive 1 dose of belumosudil 40 mg/mL in oral suspension in the following sequence: Regimen B (delivered by Vehicle 2); Regimen C (delivered by Vehicle 3); Regimen A (delivered by Vehicle 1); Regimen D (delivered by Vehicle 4); Regimen F (delivered by Vehicle 6); Regimen E (delivered by Vehicle 5)

    Drug: Part 1: Belumosudil 40 mg/mL Sequence BCADFE

  • Experimental
    Part 1: Belumosudil Sequence CDBEAF

    Subjects receive 1 dose of belumosudil 40 mg/mL in oral suspension in the following sequence: Regimen C (delivered by Vehicle 3); Regimen D (delivered by Vehicle 4); Regimen B (delivered by Vehicle 2); Regimen E (delivered by Vehicle 6); Regimen A (delivered by Vehicle 1); Regimen F (delivered by Vehicle 6)

    Drug: Part 1: Belumosudil 40 mg/mL Sequence CDBEAF

  • Experimental
    Part 1: Belumosudil Sequence DECFBA

    Subjects receive 1 dose of belumosudil 40 mg/mL in oral suspension in the following sequence: Regimen D (delivered by Vehicle 4); Regimen E (delivered by Vehicle 5); Regimen C (delivered by Vehicle 3); Regimen F (delivered by Vehicle 6); Regimen B (delivered by Vehicle 2); Regimen A (delivered by Vehicle 1)

    Drug: Part 1: Belumosudil 40 mg/mL Sequence DECFBA

  • Experimental
    Part 1: Belumosudil Sequence EFDACB

    Subjects receive 1 dose of belumosudil 40 mg/mL in oral suspension in the following sequence: Regimen E (delivered by Vehicle 5); Regimen F (delivered by Vehicle 6); Regimen D (delivered by Vehicle 4); Regimen A (delivered by Vehicle 1); Regimen C (delivered by Vehicle 3); Regimen B (delivered by Vehicle 2)

    Drug: Part 1: Belumosudil 40 mg/mL Sequence EFDACB

  • Experimental
    Part 1: Belumosudil Sequence FAEBDC

    Subjects receive 1 dose of belumosudil 40 mg/mL in oral suspension in the following sequence: Regimen F (delivered by Vehicle 6); Regimen A (delivered by Vehicle 1); Regimen E (delivered by Vehicle 5); Regimen B (delivered by Vehicle 2); Regimen D (delivered by Vehicle 4); Regimen C (delivered by Vehicle 3).

    Drug: Part 1: Belumosudil 40 mg/mL Sequence FAEBDC

  • Experimental
    Part 2: Belumosudil Sequence GHI

    Subjects receive 1 dose in the following sequence; Regimen G (belumosudil 200 mg tablet fed); Regimen H (powder for oral suspension or oral suspension belumosudil 200 mg fasted); Regimen I (powder for oral suspension or oral suspension belumosudil 200 mg fed)

    Drug: Part 2: Belumosudil 200 mg Sequence GHI

  • Experimental
    Part 2: Belumosudil Sequence HIG

    Subjects receive 1 dose in the following sequence: Regimen H (powder for oral suspension or oral suspension belumosudil 200 mg fasted); Regimen H (powder for oral suspension or oral suspension belumosudil 200 mg fed); Regimen G (belumosudil 200 mg tablet fed)

    Drug: Part 2: Belumosudil 200 mg Sequence HIG

  • Experimental
    Part 2: Belumosudil Sequence IGH

    Subjects receive 1 dose in the following sequence: Regimen I (powder for oral suspension or oral suspension belumosudil 200 mg fed); Regimen G (belumosudil 200 mg tablet fed); Regimen H (powder for oral suspension or oral suspension belumosudil 200 mg fasted)

    Drug: Part 2: Belumosudil 200 mg Sequence IGH

  • Experimental
    Part 2: Belumosudil Sequence IHG

    Subjects receive 1 dose in the following sequence: Regimen I (powder for oral suspension or oral suspension belumosudil 200 mg fed); Regimen H (powder for oral suspension or oral suspension belumosudil 200 mg fasted); Regimen G (belumosudil 200 mg tablet fed)

    Drug: Part 2: Belumosudil 200 mg Sequence IHG

  • Experimental
    Part 2: Belumosudil Sequence GIH

    Subjects receive 1 dose in the following sequence: Regimen G (belumosudil 200 mg tablet fed); Regimen I (powder for oral suspension or oral suspension belumosudil 200 mg fed); Regimen H (powder for oral suspension or oral suspension belumosudil 200 mg fasted)

    Drug: Part 2: Belumosudil 200 mg Sequence GIH

  • Experimental
    Part 2: Belumosudil Sequence HGI

    Subjects receive 1 dose in the following sequence: Regimen H (powder for oral suspension or oral suspension belumosudil 200 mg fasted); Regimen G (belumosudil 200 mg tablet); Regimen I (powder for oral suspension or oral suspension belumosudil 200 mg fed);

    Drug: Part 2: Belumosudil 200 mg Sequence HGI

Interventions

  • DrugPart 1: Belumosudil 40 mg/mL Sequence ABFCED

    Drug page: Belumosudil

    Oral suspension belumosudil 40 mg/mL in sequence Regimen A, then Regimen B, then Regimen F, then Regimen C, then Regimen E, then Regimen D

    Also known as: KD025

  • DrugPart 1: Belumosudil 40 mg/mL Sequence BCADFE

    Drug page: Belumosudil

    Oral suspension belumosudil 40 mg/mL in sequence Regimen B, then Regimen C, then Regimen A, then Regimen D, then Regimen F, then Regimen E

    Also known as: KD025

  • DrugPart 1: Belumosudil 40 mg/mL Sequence CDBEAF

    Drug page: Belumosudil

    Oral suspension belumosudil 40 mg/mL in sequence Regimen C, then Regimen D, then Regimen B, then Regimen E, then Regimen A, then Regimen F

    Also known as: KD025

  • DrugPart 1: Belumosudil 40 mg/mL Sequence DECFBA

    Drug page: Belumosudil

    Oral suspension of belumosudil 40 mg/mL in sequence Regimen D, then Regimen E, then Regimen C, then Regimen F, then Regimen B, then Regimen A

    Also known as: KD025

  • DrugPart 1: Belumosudil 40 mg/mL Sequence EFDACB

    Drug page: Belumosudil

    Oral suspension of belumosudil 40 mg/mL in sequence Regimen E, then Regimen F, then Regimen D, then Regimen A, then Regimen C, then Regimen C

    Also known as: KD025

  • DrugPart 1: Belumosudil 40 mg/mL Sequence FAEBDC

    Drug page: Belumosudil

    Oral suspension of belumosudil 40 mg/mL in sequence Regimen F, then Regimen A, then Regimen E, then Regimen B, then Regimen D, then Regimen C

    Also known as: KD025

  • 1 dose of belumosudil 200 mg in sequence Regimen G (tablet), then Regimen H (oral suspension; subject fasted), then Regimen I (oral suspension; subject fed)

    Also known as: KD025

  • 1 dose of belumosudil 200 mg in sequence Regimen H (oral suspension; subject fasted), then Regimen I (oral suspension; subject fed), then Regimen G (tablet)

    Also known as: KD025

  • 1 dose of belumosudil 200 mg in sequence Regimen I (oral suspension; subject fed), then Regimen G (tablet), then Regimen H (oral suspension, subject fasted)

    Also known as: KD025

  • 1 dose of belumosudil 200 mg in sequence Regimen I (oral suspension; subject fed), then Regimen H (oral suspension; subject fasted), then Regimen G (tablet)

    Also known as: KD025

  • 1 dose of belumosudil 200 mg in sequence Regimen G (tablet), then Regimen I (oral suspension; subject fed), then Regimen H (oral suspension; subject fasted)

    Also known as: KD025

  • 1 dose of belumosudil 200 mg in sequence Regimen H (oral suspension; subject fasted), then Regimen G (tablet), then Regimen I (oral suspension; subject fed)

    Also known as: KD025

06

What researchers measure

Primary outcomes

  1. Comparison of Taste/Palatability Questionnaire for Regimens B, C, D, E, F vs. Regimen A (Part 1 Only)

    Comparison of Taste/Palabability Questionnaire results of (1) Regimen B (belumosudil 400 mg/mL using Vehicle 2) vs. Regimen A (belumosudil 400 mg/mL using Vehicle 1); (2) Regimen C (belumosudil 400 mg/mL using Vehicle 3) vs. Regimen A; (3) Regimen D (belumosudil 40 mg/mL using Vehicle 4) vs. Regimen A; (4) Regimen E (belumosudil 40 mg/mL using Vehicle 5) vs. Regimen A; and (5) Regimen F (belumosudil 40 mg/mL using Vehicle 5) vs. Regimen A. The Taste/Probability Questionnaire assess smell, sweetness, bitterness, flavor, mouth feel/texture, grittiness, and aftertaste. Subjects rate each sense on a categorical scale ranging from extreme dislike to extreme like.

    Time frame: Immediately after dosing

  2. Selection of Belumosudil Suspension Formulation for Part 2

    Selection of the belumosudil suspension formulation to be used in Part 2 of the study

    Time frame: After administration of belumosudil 40 mg/mL with each of the 6 vehicles in the sequence assigned

Secondary outcomes

  1. Pharmacokinetics (Part 2 Only): Relative Bioavailability of Regimen I vs. Regimen G

    Comparison of Regimen I (powder for oral suspension or oral suspension of belumosudil 200 mg fed) vs. Regimen G (belumosudil 200 mg tablet fed)

    Time frame: Up to 72 hours post-dose

  2. Pharmacokinetics (Part 2 Only): Determination of Tlag of Belumosudil 200 mg

    Assessment of the time prior to the first measurable concentration (Tlag) of oral belumosudil 200 mg

    Time frame: Up to 72 hours post-dose

  3. Pharmacokinetics (Part 2 Only): Determination of Tmax of Belumosudil 200 mg

    Assessment of the time of maximum observed concentration (Tmax) of oral belumosudil 200 mg

    Time frame: Up to 72 hours post-dose

  4. Pharmacokinetics (Part 2 Only): Determination of Cmax of Belumosudil 200 mg

    Assessment of the maximum observed concentration (Cmax) of oral belumosudil 200 mg

    Time frame: Up to 72 hours post-dose

  5. Pharmacokinetics (Part 2 Only): Determination of AUC(0-24) of Belumosudil 200 mg

    Assessment of the area under the concentration-time curve from time 0 to 24 hours post-dose (AUC\[0-24\]) of oral belumosudil 200 mg

    Time frame: Up to 72 hours post-dose

  6. Pharmacokinetics (Part 2 Only): Determination of AUC(0-last) of Belumosudil 200 mg

    Assessment of the area under the concentration-time curve from time 0 to the time of last measurable concentration (AUC\[0-last\]) of oral belumosudil 200 mg

    Time frame: Up to 72 hours post-dose

  7. Pharmacokinetics (Part 2 Only): Determination of AUC(0-inf) of Belumosudil 200 mg

    Assessment of the area under the concentration-time curve from time 0 extrapolated to infinity (AUC\[0-inf\]) of oral belumosudil 200 mg

    Time frame: Up to 72 hours post-dose

  8. Pharmacokinetics (Part 2 Only): Determination of AUC%extrap of Belumosudil 200 mg

    Assessment of the area under the concentration-time curve from the time of the last measurable concentration to infinity as a percentage of the area under the concentration-time curve extrapolated to infinity (AUC%extrap) of oral belumosudil 200 mg

    Time frame: Up to 72 hours post-dose

  9. Pharmacokinetics (Part 2 Only): Determination of t1/2 of Belumosudil 200 mg

    Assessment of the terminal elimination half-life (t1/2) of oral belumosudil 200 mg

    Time frame: Up to 72 hours post-dose

  10. Pharmacokinetics (Part 2 Only): Determination of Lambda-z of Belumosudil 200 mg

    Assessment of the first order rate constant associated with the terminal (log-linear) portion of the concentration-time curve (Lambda-z) of oral belumosudil 200 mg

    Time frame: Up to 72 hours post-dose

  11. Pharmacokinetics (Part 2 Only): Determination of CL/F of Belumosudil 200 mg

    Assessment of the total body clearance calculated after a single extravascular administration where F (fraction of dose bioavailable) is unknown (belumosudil only), i.e., CL/F

    Time frame: Up to 72 hours post-dose

  12. Pharmacokinetics (Part 2 Only): Determination of Vz/F of Belumosudil 200 mg

    Assessment of the apparent volume of distribution based on the terminal phase calculated using AUC(0-inf) after a single extravascular administration where the fraction of dose bioavailable (F) is unknown (belumosudil only), i.e., Vz/F

    Time frame: Up to 72 hours post-dose

  13. Pharmacokinetics (Part 2 Only): Determination of Frel Cmax of Belumosudil 200 mg

    Assessment of the relative bioavailability based on Cmax, i.e., Frel Cmax, of oral belumosudil 200 mg

    Time frame: Up to 72 hours post-dose

  14. Pharmacokinetics (Part 2 Only): Determination of Frel AUC(0-last) of Belumosudil 200 mg

    Assessment of the relative bioavailability based on AUC(0-last), i.e., Frel AUC(0-last), of oral belumosudil 200 mg

    Time frame: Up to 72 hours post-dose

  15. Pharmacokinetics (Part 2 Only): Determination of Frel AUC(0-inf) of Belumosudil 200 mg

    Assessment of the relative bioavailability based on AUC(0-inf), i.e., Frel AUC(0-inf), of oral belumosudil 200 mg

    Time frame: Up to 72 hours post-dose

  16. Pharmacokinetics (Part 2 Only): MPR Cmax of Belumosudil 200 mg

    Metabolite-to-parent ratio (MPR) based on the Cmax of metabolite KD025m1 and metabolite KD025m2 of belumosudil 200 mg orally

    Time frame: Up to 72 hours post-dose

  17. Pharmacokinetics (Part 2 Only): MPR AUC(0-last) of Belumosudil 200 mg

    Metabolite-to-parent ratio (MR) based on AUC(0-last) of metabolite KD025m1 and metabolite KD025m2 only, i.e., MPR AUC(0-last)

    Time frame: Up to 72 hours post-dose

  18. Pharmacokinetics (Part 2 Only): MPR AUC(0-inf) of Belumosudil 200 mg

    Metabolite-to-parent ratio based on AUC(0-inf) of metabolite KD025m1 and metabolite KD025m2, i.e., MPR AUC(0-inf)

    Time frame: Up to 72 hours post-dose

  19. Safety: Incidence, Intensity, and Relationship of AEs to Belumosudil 200 mg

    Proportion of subjects with adverse events (AEs) overall, by intensity, and by relationship to oral belumosudil 200 mg

    Time frame: Up to 7 days after the last dose (duration of study)

  20. Safety: Incidence, Intensity, and Relationship of SAEs to Belumosudil 200 mg

    Proportion of subjects with serious adverse events (SAEs) overall, by intensity, and by relationship to oral belumosudil 200 mg

    Time frame: Up to 7 days after the last dose (duration of study)

  21. Safety: Incidence, Intensity, and Relationship of AEs Leading to Discontinuation from the Study

    Proportion of subjects who had AEs leading to discontinuation from the study, by intensity, and by relationship to oral belumosudil 200 mg

    Time frame: Up to 7 days after the last dose (duration of study)

07

Study locations

1 site
  • Quotient Sciences
    Nottingham, England NG11 6J5, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2020 to primary completion in Sep 2021, 10 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 13, 2021
First posted
Feb 3, 2021
StartActual
Oct 26, 2020
Primary completionActual
Sep 3, 2021
CompletionActual
Sep 3, 2021
Last update
May 11, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 11, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04735822
Collaborators
Quotient Sciences
Responsible party
Sponsor
First posted
Feb 3, 2021
Start date
Oct 26, 2020
Primary completion
Sep 3, 2021
Completion
Sep 3, 2021
Last update
May 11, 2022

Study contacts

Nand Singh, BSc, MD, DPM
principal investigator · Quotient Sciences

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Belumosudil

Start the discussion